Tumor Monitoring Solutions: From Diagnosis to Recurrence
Our FFPE TMB, gDNA TMB, MRD, and bTMB products are designed to support all stages of solid tumor treatment and recurrence monitoring. All products feature hundreds of clinically relevant mutations and come with comprehensive variant data. Validate your complete workflow!

Immortalized Patient-Derived Cell Line


TMB (Tumor Mutational Burden)
Our FFPE TMB and gDNA TMB reference materials are derived from tumor-normal patient samples, ensuring accurate mutation burden assessment.
Real-world accuracy and comprehensive support for solid tumor treatments.

MRD (Minimal Residual Disease)
Our Seraseq ctDNA MRD Panel Mix is derived from our TMB Score 26 cell line. MRD Panel Mix supports both tumor-informed MRD when paired with our TMB Score 26 gDNA and/or FFPE product and supports tumor-naïve workflows with the spike-in of 25 canonical cancer mutations for monitoring minimal residual disease.
Detects low levels of residual disease, aiding in early recurrence detection.

bTMB (Blood Tumor Mutational Burden)
Our Seraseq Blood TMB Mix provides a non-invasive option for measuring tumor mutational burden using blood samples.
Offers a reliable alternative to tissue biopsies for monitoring mutation burden.
Categorizing by TMB Scores/ Cell lines/ Patient-of-origin
For the ease of navigation and understanding, our products can also be categorized based on their TMB scores, representing the number of mutations in a tumor's DNA. Higher TMB scores can indicate that a patient is more likely to respond well to certain immunotherapies, leading to a better treatment approach.
Score 26 Reference Materials
Score 20 Reference Materials
Score 9 Reference Materials
Why Choose Seraseq TMB & MRD?
- Patient-Derived: Authentic tumor mutation profile
- Matched Materials: Consistent references across sample types
- Flexible Options: Support for tumor-informed and tumor-naïve approaches
- Comprehensive Data: WES or targeted panel VCF files included
Ready to Enhance Your Workflow?
- Need specific tumor percentages or variants? Contact us to discuss custom reference material options.